SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001104659-18-019895
Filing Date
2018-03-23
Accepted
2018-03-23 17:27:52
Documents
1
Group Members
NOVARTIS AG

Document Format Files

Seq Description Document Type Size
1 SC 13D/A a18-8921_1sc13da.htm SC 13D/A 235390
  Complete submission text file 0001104659-18-019895.txt   236939
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Subject) CIK: 0001652130 (see all company filings)

IRS No.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-89486 | Film No.: 18711152
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
Office of Life Sciences

Mailing Address 250 MASSACHUSETTS AVENUE CAMBRIDGE MA 02139
Business Address 250 MASSACHUSETTS AVENUE CAMBRIDGE MA 02139 (617) 871-8000
Novartis Institutes for BioMedical Research, Inc. (Filed by) CIK: 0001673852 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A